Quick Answer
Grace Therapeutics, Inc. reported R&D Expense of $9.51 million for fiscal year 2025.
Grace Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $9.51M | +103.1% |
| 2024 | $4.68M | -53.0% |
| 2023 | $9.97M | +79.4% |
| 2022 | $5.56M | +33.2% |
| 2021 | $4.17M | -73.9% |
| 2020 | $15.97M | -45.6% |
| 2019 | $29.37M | +87.5% |
| 2018 | $15.67M | +104.7% |
| 2017 | $7.65M | +5.9% |
| 2017 | $7.23M | -4.5% |
| 2016 | $7.57M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $462.0K | -78.9% | -18.7% |
| September 30, 2025 | $568.0K | -80.9% | -40.5% |
| June 30, 2025 | $955.0K | -64.7% | -56.5% |
| December 31, 2024 | $2.19M | +52.0% | -26.3% |
| September 30, 2024 | $2.98M | +547.0% | +9.9% |
| June 30, 2024 | $2.71M | +147.3% | +87.7% |
| December 31, 2023 | $1.44M | -41.1% | +213.7% |
| September 30, 2023 | $460.0K | -86.0% | -58.0% |
- Grace Therapeutics, Inc. showed an increase of +103.1% in R&D Expense compared to the prior fiscal year.
- Over the 2016–2025 period, Grace Therapeutics, Inc.’s r&d expense has grown by 25.7% (from $7.57 million to $9.51 million).
- The most recent figure is from Grace Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 23, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: